Enterome partners with Vertex over treatment of inflammatory bowel diseases

19 April 2016
2019_biotech_test_vial_discovery_big

French company Enterome Bioscience has signed an exclusive worldwide license agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) to research, develop and commercialize novel small molecule FimH antagonists to treat inflammatory bowel diseases (IBD).

Enterome, which specializes in the development of pharmaceuticals and diagnostics based on the gut microbiome, plans to take EB 8018, the lead compound in this program, into first human clinical trials this year, as well as a companion diagnostic to identify patients with inflammatory bowel diseases (IBD) who will benefit from their use.

Through application of its metagenomics platform, Enterome has identified a key bacterial species – adherent-invasive Escherichia coli (AIEC) – which is responsible for triggering inflammation in IBD.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology